Suppression of proline-directed protein kinase FA inhibits the malignant growth of human pancreatic ductal adenocarcinoma

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1489-1494

  Fu, Hsiao Hui ^a   Yang, Shiaw Der ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Pancreatic ductal adenocarcinoma; PDPK FA

Indexed keywords

PHOSPHATASE; PROLINE DIRECTED PROTEIN KINASE FA; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CLONE; CLONOGENESIS; CONTROLLED STUDY; ENZYME REPRESSION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SCID MOUSE; TUMOR VOLUME;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; DNA, ANTISENSE; FEMALE; HUMANS; MICE; MICE, SCID; PANCREATIC NEOPLASMS; PROLINE-DIRECTED PROTEIN KINASES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 3242734960     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
3. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H and Buchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358: 1576-1585, 2001.
4. Gullo L, Tomassetti P, Migliori M, Casadei R and Marrano D: Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis? Pancreas 22: 210-213, 2001.
5. Snady H, Bruckner H, Cooperman A, Paradiso J and Kiefer L: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89: 314-327, 2000.
6. Lillemoe KD, Yeo CJ and Cameron JL: Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 50: 241-268, 2000.
7. Kelly DM and Benjamin IS: Pancreatic carcinoma. Ann Oncol 6: 19-28, 1995.
8. Warshaw AL and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
9. Yang SD, Vandenheede JR, Goris J and Merlevede W: ATP.Mg-dependent protein phosphatase from rabbit skeletal muscle. I. Purification of the enzyme and its regulation by the interaction with an activating protein factor. J Biol Chem 255: 11759-11767, 1980.
10. Vandenheede JR, Yang SD, Goris J and Merlevede W: ATP.Mg-dependent protein phosphatase from rabbit skeletal muscle. II. Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity. J Biol Chem 255: 11768-11774, 1980.
11. A). Adv Prot Phosphatase 6: 133-157, 1991.
12. A. J Chin Biochem Soc 23: 123-134, 1994.
13. A enhances chemosensitivity in human prostate cancer cells. Clin Cancer Res 6: 1024-1030, 2000.
14. A expression inhibits the growth of human chronic myeloid leukaemia cells. Br J Cancer 82: 1480-1484, 2000.
15. A expression potentiates erythroid differentiation of human myeloid leukemia cells. Cancer 89: 1004-1011, 2000.
16. A systemically inhibits the growth of human acute leukemia cells. Int J Cancer 91: 650-653, 2001.
17. A potentiates apoptotic induction and greatly enhances chemosensitivity in human acute lymphoblastic leukemia cells. Cancer 92: 1753-1758, 2001.
18. A with chemoresistance, invasion, and recurrence in patients with bladder carcinoma. Cancer 95: 775-783, 2002.
19. A with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer 95: 1840-1847, 2002.
20. Rizzino A: Soft agar growth assays for transforming growth factors and mitogenic peptides. Methods Enzymol 146: 341-352, 1987.
21. A in human prostate carcinoma cells. Anticancer Res 18: 1117-1121, 1998.